Edition:
United Kingdom

Pacira Pharmaceuticals Inc (PCRX.OQ)

PCRX.OQ on NASDAQ Stock Exchange Global Select Market

44.80USD
8 Dec 2017
Change (% chg)

$0.60 (+1.36%)
Prev Close
$44.20
Open
$44.50
Day's High
$45.15
Day's Low
$43.80
Volume
134,819
Avg. Vol
178,658
52-wk High
$58.80
52-wk Low
$29.90

Latest Key Developments (Source: Significant Developments)

Pacira Pharmaceuticals reports Q3 non-gaap earnings per share $0.11
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Pacira Pharmaceuticals Inc :Pacira Pharmaceuticals Inc reports third quarter 2017 financial results.Q3 non-gaap earnings per share $0.11.Q3 gaap loss per share $0.19.Q3 revenue $67.3 million versus I/B/E/S view $69.6 million.Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.Pacira Pharmaceuticals Inc - ‍Full-year exparel net product sales guidance revised to $280 to $285 million​.Pacira Pharmaceuticals Inc - ‍Updating its full year 2017 sales guidance and reiterating its remaining financial guidance​.FY2017 revenue view $291.8 million -- Thomson Reuters I/B/E/S.  Full Article

Pacira Pharma to invest up to $25 million in Tela Bio
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Pacira Pharmaceuticals Inc :Committed to invest up to $25 million in Tela Bio, a privately-held surgical reconstruction company​.Under terms of agreement, Pacira will make an initial investment of $15 million​.Under terms of agreement, Pacira is entitled to one seat on Tela Bio board of directors​.Agreement also includes a standstill provision precluding a change of control in Tela Bio for at least 12 months​.  Full Article

Pacira Pharmaceuticals announces FDA acceptance of SNDA
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Pacira Pharmaceuticals Inc :Pacira Pharmaceuticals announces FDA acceptance of SNDA for exparel as a nerve block to produce regional analgesia.Pacira Pharmaceuticals Inc - ‍expected action date by FDA under Prescription Drug User Fee Act (PDUFA) is April 6, 2018​.  Full Article

Pacira Pharmaceuticals Q2 GAAP loss per share $0.21
Thursday, 4 Aug 2016 

Pacira Pharmaceuticals Inc : Q2 GAAP loss per share $0.21 . Q2 non-GAAP earnings per share $0.19 . Q2 earnings per share view $0.03 -- Thomson Reuters I/B/E/S .Q2 revenue $69.6 million versus I/B/E/S view $67.1 million.  Full Article

Pacira Pharmaceuticals to pay termination fee of about $7.3 mln to CrossLink
Friday, 1 Jul 2016 

Pacira Pharmaceuticals : In connection with termination of agreement, fee based on percentage of earned performance-based fees will be due to CrossLink . Termination fee in connection with agreement with CrossLink Bioscience related to promotion and sale of exparel . The fee, estimated to be about $7.3 million, is payable to CrossLink quarterly over two years beginning in Q4 of 2016 Source: (http://1.usa.gov/29ah9lF ) Further company coverage: [PCRX.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

BRIEF-Pacira announces FDA advisory committee meeting to review sNDA for Exparel

* Pacira announces FDA advisory committee meeting to review sNDA for Exparel as a nerve block for regional analgesia